SLS Stock Summary and Trading Ideas (Sellas Life Sciences Group | NASDAQ:SLS)

SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Sellas Life Sciences Group trades on the NASDAQ stock market under the symbol SLS.

As of April 28, 2026, SLS stock price was flat at $4.88 with 3,037,519 million shares trading.

SLS has a beta of 0.80, meaning it tends to be less sensitive to market movements. SLS has a correlation of 0.01 to the broad based SPY ETF.

SLS has a market cap of $900.52 million. This is considered a Small Cap stock.

In the last 3 years, SLS traded as high as $6.14 and as low as $.50.

The top ETF exchange traded funds that SLS belongs to (by Net Assets): XBI, VTI, IWM, VXF, IWO.

SLS has outperformed the market in the last year with a return of +248.6%, while the SPY ETF gained +30.6%. In the last 3 month period, SLS beat the market returning +10.9%, while SPY returned +2.6%. However, in the most recent 2 weeks SLS has underperformed the stock market by returning +2.5%, while SPY returned +3.7%.

SLS support price is $4.64 and resistance is $5.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLS shares will trade within this expected range on the day.